CoChat

Comparative long‐term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20–40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia

Gumprecht, J., Gosho, M., Budinski, D., Hounslow, N. · 2011 · Diabetes, Obesity and Metabolism
Cited by 81

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aim: To compare the long‐term efficacy and safety of pitavastatin with atorvastatin in patients with type 2 diabetes and combined (mixed) dyslipidaemia. Methods: Randomised, double‐blind, active‐controlled, multinational non‐inferiority study. Patients were randomised 2 : 1 to pitavastatin 4 mg (n = 279) or atorvastatin 20 mg (n = 139) daily for 12 weeks. Patients completing the core study could continue on pitavastatin 4 mg (n = 141) or atorvastatin 20 mg (n = 64) [40 mg (n = 7) if lipid targets not reached by week 8] for a further 44 weeks (extension study). The primary efficacy variable was the change in low‐density lipoprotein cholesterol (LDL‐C). Results: Reductions in LDL‐C were not significantly different at week 12 between the pitavastatin (−41%) and atorvastatin (−43%) groups. Attainment of National Cholesterol Education Program and European Atherosclerosis Society targets for LDL‐C and non‐high‐density lipoprotein cholesterol (non‐HDL‐C) was similarly high for both treatment groups. Changes in secondary lipid variables (e.g. HDL‐C, apolipoprotein B and triglycerides) were similar between treatments. Post hoc analysis showed that adjusted mean treatment differences for pitavastatin vs. atorvastatin were within the non‐inferiority margin at weeks 16 (+0.11%; 95% confidence interval (CI), −5.23 to 5.44) and 44 (−0.02%; 95% CI, −5.46 to 5.41) of the extension study. Both treatments were well tolerated; atorvastatin increased fasting blood glucose from baseline (+7.2%; p < 0.05), whereas pitavastatin had no significant effect (+2.1%). Conclusions: Reductions in LDL‐C and changes in other lipids were not significantly different in patients treated with pitavastatin 4 mg or atorvastatin 20 or 40 mg. Pitavastatin may, however, have a more favourable effect on the glycaemic status.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2011.01477.x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 81

Metadata

Authors
Gumprecht, J., Gosho, M., Budinski, D., & Hounslow, N.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2011-09-28
Volume
13
Issue
11
Pages
1047-1055
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2139324959
Cited by
81
References
8
FWCI
7.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.